Paul is an accomplished business leader with extensive experience as a non-executive director and chairman of public companies. He has served in multiple executive positions including CEO, COO, CFO, and Company Secretary at various corporations listed on the ASX and NASDAQ. Currently, Paul is Managing Director of Braddon Capital, a globally-focused venture capital firm. There, he specializes in commercialization, corporatization, and mergers and acquisitions, with a focus on emerging deep technologies. His diverse executive and board experience provides valuable strategic guidance as GenEmbryomics scales its operations and expands access to its genomic testing services.

Nick Murphy founded GenEmbryomics after dedicating his career to genetics research and its applications in assisted reproductive technology, immunogenetics, and polygenic risk assessment. With over ten years of experience in the IVF industry, he launched GenEmbryomics to develop innovative genomic testing solutions for embryo screening. The company's flagship test, PGT-WGS, represents the world's first whole genome sequencing-based assay to evaluate embryonic genetic health. With its introduction, PGT-WGS is set to enable improved IVF outcomes for fertility clinics and patients globally. Under Dr. Murphy's leadership, GenEmbryomics continues to leverage the latest genetic technologies to advance the field of reproductive genomics and provide new ways to aid patients struggling with infertility.

Santiago Munné is an internationally recognized leader in reproductive genetics. Since earning his PhD in Human Genetics from the University of Pittsburgh in 1991, he has published over 200 scientific papers on preimplantation genetic testing, chromosome abnormalities, and personalized infertility diagnostics. Dr. Munné frequently lectures globally and co-founded the Preimplantation Genetic Diagnosis International Society, serving as President and board member. He is the CIO at Overture Life and is the founder of multiple genomics companies including Reprogenetics, Recombine, Phosphorus, MedAnswers, and G1 Sciences. His groundbreaking research and innovations in the field of reproductive and infertility genetics have positioned him as a pioneer in genetic testing and infertility treatment.

Nick is a highly qualified and contemporary independent Non-Executive Director and Audit and Risk Committee Chair, with strong ASX and NASDAQ listed entity expertise and an exemplary professional career spanning over 30 years. Nick’s expertise is sought across a wide breadth of industry sectors encompassing, genetics and life sciences, aquaculture, FMCG, water and sewerage, infrastructure, advanced manufacturing, renewable energy, drone technology, forestry public transport, agribusiness, tourism and hospitality and the visitor economy, education and the VET sector, civil engineering / construction, and finance / valuations. Nick is a Fellow of the Australian Institute of Company Directors, the Institute of Chartered Accountants of Australia, the Governance Institute of Australia, the Tax Institute of Australia and the Financial Services Institute of Australasia

Tess Burleson has over 25 years of progressive experience in advising and developing key business support operations for life sciences companies, as well as in support of new company formation in the biotech industry. She has a passion for building new companies and creating structure to enable high growth and scale. Ms. Burleson has served on numerous boards, including a NASDAQ traded pharmaceutical company and private company boards. She serves as an advisor for businesses in life sciences, financial services, as well as for social impact organizations. She is a licensed Certified Public Accountant (CPA) with experience in taxation, assurance, and advisory services. She achieved her Advanced Finance certification from The Wharton School at the University of Pennsylvania, and her undergraduate and graduate degrees in Accounting and Finance from Anderson School of Management at UNM.

Saadia Basharat leverages a decade of experience as a management Consultant to the pharma, biotechnology and technology transfer industries. Since earning her PhD in Neuroendocrinology from Imperial College London, she has advised more than 100 life science companies and investors during her time as a professional Consultant. Dr Basharat is passionate about helping biotech and pharma companies translate scientific ideas into products that truly benefit patients. Her expertise spans technical and commercial due diligence, business planning, and partnering and licensing.